Conference Day One
Thursday 19th January 2006


08.30 Coffee and registration

09.00 Chairman's opening remarks

Dr. Michael Christensen
Head of Drug Metabolism
Novo Nordisk

09.15 Getting Value from Your ADME Data: Effective Decision-making in Early Discovery

Dr. Alan P. Beresford
Associate Director: Lead Optimisation
Inpharmatica Ltd.

10.00 Optimal Early ADME Screening

Dr. Michael Christensen
Head of Drug Metabolism
Novo Nordisk


10.45 Networking coffee break


11.15 Histologically Defined Biomarkers in Drug Development

Mr. Martin Shaw
Senior Scientific Officer
Biotrin International Ltd.

12.00 Increasing Throughput in Pharmacokinetic Studies

Dr. Kelvin Hughes
Technology Manager, Assay Development
GE Healthcare Biosciences


12.45 Networking Lunch


14.15 Integration of High Throughput ADME Screening and Pharmacokinetic Simulation for Acceleration of Drug Discovery

Dr. Darwin Cheney
Chief Scientific Officer
Cyprotex

15.00 In Silico ADME/Tox Prediction: Crossing the Credibility Chasm.

Dr. Gregory Banik
General Manager, Informatics
Bio-Rad Laboratories Inc.


15.45 Coffee break


16.00 Systems Biology Approach to In-Silico Modeling of Biological Pathways: Towards Elucidating Molecular Mechanisms of Toxicity

Dr. Gordana Apic
CEO
Cambridge Cell Networks

16.45 Predictive Toxicogenomics at the Crossroads

Dr. Andreas Hohn
Genedata AG

17.30 Panel Discussion

This session will provide an opportunity for all day one speakers and delegates to explore key issues that have arisen over the day.

18.00 Chair's Closing Remarks

18.30 End of Day One



Conference Day Two
Friday 20h January 2006


08.30 Coffee and registration

09.00 Chairman's opening remarks

Dr. Terry Riss
R&D Scientist, Cellular Analysis
Promega Corporation

09.15 Comparison of different materials and surface functionalization technologies for optical bottom plates

Dr. Benedikt Busse, zell-kontakt GmbH,
Mr. Denis J. Moller, Nunc A/S


10.00 Choosing Appropriate In Vitro Toxicity Assays for Multiplexing

Dr. Terry Riss
R&D Scientist, Cellular Analysis
Promega Corporation


10.45 Networking coffee break


11.15 In Vitro Hepatotoxicity Assays in Drug Development

Dr. Nicky Hewitt
European Business Development
In Vitro Technologies Inc

12.00 Cell-based Models to Study Hepatic Drug Metabolism and Enzyme Induction in Humans

Dr. Willem Meuldermans
Global Sr. Preclin. PK Expert
Johnson & Johnson


12.45 Networking lunch


14.15 High Concordance of Drug-Induced Human Hepatotoxicity with in vitro Cytotoxicity Measured in a Novel Cell-based Model Using High Content Screening

Dr. Peter O'Brien
Laboratory Head in Safety Sciences
Pfizer

15.00 Propagation of Biological and Genetic Interindividual Variability of Metabolism to PK/PD/Tox: Implications for Study Design

Dr. Amin Rostami
Reader in Clinical Pharmacokinetics and Drug Metabolism
University of Sheffield
Director of Scientific Development
Simcyp Limited


15.45 Coffee break


16.00 Global In Vitro Predictive Stem Cell Hemotoxicology For Early Drug Screening, Safety Assesment and Estimating Pre-Clinical and Human Clinical Trial Dosing

Dr. Ivan N. Rich
Chairman & CEO
HemoGenix, Inc.

16.45 Why Pharmacovigilance?

Dr. I. Ralph Edwards
Director, International Drug Monitoring
World Health Organization

17.30 Panel Discussion

This session will provide an opportunity for all day two speakers and delegates to explore key issues that have arisen over the day.

18.00 Closing Comments from the Chair

18.30 Close Conference